Please login to the form below

Not currently logged in
Email:
Password:

CRVO

This page shows the latest CRVO news and features for those working in and with pharma, biotech and healthcare.

NICE backs Bayer’s Eylea as first-line BRVO treatment

NICE backs Bayer’s Eylea as first-line BRVO treatment

vein occlusion ( CRVO), diabetic macular oedema ( DMO), and myopic choroidal neovascularisation (mCNV).

Latest news

More from news
Approximately 1 fully matching, plus 16 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Purple Agency

An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....

Latest intelligence

Guide
How to embrace behavioural science principles in healthcare MR...
Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
Employee wellbeing in creative agencies: three tips to get you started
Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...